Circio announces in vivo proof-of-concept for its circVec circular RNA platform technology and reinforced gene therapy focus
· circVec results demonstrate significantly enhanced protein expression and durability vs. conventional mRNA-based expression with DNA vectors in vivo · Circio´s R&D strategy is centered on gene therapy, where circVec can deliver substantial improvement over current gold-standard approaches · Circio has selected AAV-based gene therapy for Alpha-1-antitrypsin deficiency (AATD) as the lead program · Circio aims to secure the first circVec partnering deal within twelve months · The recent circVec data and a financial update are presented in a company update webcast available on